key: cord-0261074-gm7dns20
authors: Perry, J. A.; Osman, S.; Wright, J.; Richard-Greenblatt, M.; Buchan, S. A.; Sadarangani, M.; Bolotin, S.
title: Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review
date: 2022-01-23
journal: nan
DOI: 10.1101/2022.01.21.22269667
sha: c804e1d9ef1c774af4c011efaf36bb76bfc8b097
doc_id: 261074
cord_uid: gm7dns20

Background: A correlate of protection (CoP) is an immunological marker associated with protection against infection. A CoP can be used to determine whether an individual is protected from infection, evaluate candidate vaccines, guide vaccination dosing intervals and policy, and understand population-level immunity against a pathogen. Despite an urgent need, a CoP for SARS-CoV-2 is currently undefined, leaving an evidence gap for informing public health policy and adapting it appropriately as new variants of concern emerge. The objective of this study was to systematically review and assess the evidence for a humoral SARS-CoV-2 CoP. Methods and Findings: We searched OVID MEDLINE, EMBASE, Global Health, Biosis Previews and Scopus from inception to January 4, 2022 and pre-prints (using NIH iSearch COVID-19 portfolio) from inception to December 31, 2021, for studies describing SARS-CoV-2 re-infection or breakthrough infection with associated antibody measures. Two reviewers independently extracted study data and performed quality assessment. Twenty-five studies were included in our systematic review. Several studies reported re-infection or breakthrough cases that occurred in the presence of robust antibody levels. Studies that compared aggregate antibody concentrations from individuals who experienced re-infection or breakthrough compared to those who remained protected did not always find differences that were statistically significant. However, several studies found an inverse relationship between antibody levels and infection incidence, risk, or viral load, and a correlation between antibody levels and vaccine efficacy (VE). Estimates of the contribution of antibody levels to VE varied from 48.5% to 94.2%, suggesting that both humoral immunity and other immune components contribute to protection. Only two studies estimated a quantitative CoP. For Ancestral SARS-CoV-2, these included 154 (95% confidence interval (CI) 42, 559) anti-S binding antibody units/mL (BAU/mL), and 28.6% (95% CI 19.2, 29.2%) of the mean convalescent antibody level following infection. One study reported a CoP for the Alpha (B.1.1.7) variant of concern of 171 (95% CI 57, 519) BAU/mL. As of our search date, no studies reported an Omicron-specific CoP. Conclusions: The reviewed literature was limited by a wide variation in assay methodology and antibody targets. Few studies reported SARS-CoV-2 lineage. The studies included in our review suggest that if it exists, a SARS-CoV-2 CoP is likely relative, where higher antibody levels decrease the risk of infection, but do not eliminate it completely. More work is urgently needed in this area to establish a SARS-CoV-2 CoP and guide policy as the pandemic continues.

As the COVID-19 pandemic progresses, our understanding of immunity against SARS-CoV-2 continues to 70 evolve. Both previous infection and vaccination against SARS-CoV-2 appear to provide protection against 71 infection and severe disease (1, 2), but the mechanism and durability of that protection remains unclear 72 (3, 4) . Humoral and cellular immunity likely both contribute to protection (5, 6), but it is uncertain 73 whether a correlate of protection (CoP) for SARS-CoV-2 exists, and if so, whether it is easily quantifiable 74 using a diagnostic laboratory test. Without a CoP, serological testing can confirm previous infection or 75

vaccination, but not immunity, leaving an evidence gap in public health policy particularly as new 76 variants of concern emerge. 77 determination of individual immunity, which is particularly important for immunocompromised 92 individuals (11, 12) and individuals whose immunity levels have waned (13) . At the population level, a 93

CoP may enhance the utility of serosurveys, by enabling the assessment the level of protection within a 94 community (10). 95

The search for a SARS-CoV-2 CoP is further complicated by the emergence of variants of concern (VOCs). a CoP, and raises the possibility that a SARS-CoV-2 CoP may be With this in mind, and considering that an easily measurable CoP would most likely be humoral and not 101 cellular, we performed a systematic review to assess the evidence for a humoral CoP for SARS-CoV-2. 102

Methods 104

We searched the OVID MEDLINE database for peer-reviewed articles published from database inception 106 to December 31, 2021, and the EMBASE, Global Health, Biosis Previews and Scopus databases from 107 inception to January 4, 2022. We used the NIH iSearch COVID-19 Portfolio tool to search for preprint 108 articles published from database inception to December 31, 2021. In our search strategy, we focused on 109 studies reporting either re-infection or breakthrough infection following vaccination, since both allow an 110 evaluation of humoral immune protection. All search terms used are reported in Supplementary Table 1.  111 We also searched reference lists for suitable articles, and requested article recommendations from 112 experts in the field. 113 114 6 One reviewer screened titles and abstracts using Distiller SR (Ottawa, Ontario, Canada) . Studies passed 115 title and abstract screening if their abstracts discussed re-infection with SARS-CoV-2 or breakthrough 116 infection following vaccination with COVID-19 vaccine; mentioned antibody measures specific to CoV-2; or mentioned a correlate or threshold of protection against SARS-CoV-2. We excluded studies 118 that focused on immunocompromised populations or animal models. 119

Two reviewers screened full texts of articles that met title/abstract screening criteria using defined re-120 infection and breakthrough infection criteria (Table 1) . During full-text screening, we included studies 121 reporting a quantitative CoP against SARS-CoV-2, and studies reporting re-infection or breakthrough 122 infection according to our definitions along with associated pre-infection measures for any antibody 123

isotype. If these studies reported aggregate antibody measures (i.e. geometric mean titres (GMT)) we 124 required them to include summary statistics (i.e. statistical significance testing or 95% confidence 125 intervals (95% CI)) to permit the determination of statistically significant differences between groups. 126

We also included studies that correlated antibody levels to vaccine efficacy (VE) or effectiveness, but 127 only if they provided statistical summary measures (e.g. a correlation co-efficient describing the 128 relationship between antibody level and VE), or if they correlated an antibody concentration to a VE of 129

We used the National Institutes of Health National Heart, Lung and Blood Institute (NIH NHLBI) Study 138 Quality Assessment tools to assess the quality of each study using the corresponding tools specific for 139 each study design (19) , and adapted it by adding questions to customize the tool for this study. Studies 140 correlating VE to antibody levels were evaluated using the Cohort and Cross Sectional Tool. 141

We reported our results using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 143 screening, for which our Kappa was 1.0, we included 30 articles in our review. However, only 25 articles 152 passed quality assessment. Of these, 14 described SARS-CoV-2 re-infection along with individual or 153 aggregate humoral measures (2, (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) , and 11 studies described SARS-CoV-2 breakthrough infection 154 following vaccination or statistical modelling to explore associations between VE and antibody levels 155 (34-44) ( Table 2 ). Only two studies estimated a SARS-CoV-2 antibody CoP, both using statistical 156 modelling methods (38, 39). 8 28-31, 33). Most study populations were healthcare workers, patients, or long term care home residents 161 (2, 21-24, 26, 29-33) . The remaining studies described individuals from the general population (25, 27, 162 28) . Although not always reported, specimen collection occurred between 14 days and seven months 163 after initial infection (22, 31) and between 4 days and seven months before re-infection (26, 32) . 164

Antibody test results included various commercial and laboratory developed enzyme-linked 165 immunosorbent assays (ELISAs) targeting anti-spike (anti-S), anti-receptor binding domain (anti-RBD) 166 and anti-nucleocapsid (anti-N) antibodies, as well as neutralization assays. No study utilized the World 167

Health Organization (WHO) International Standard (IS), which was developed to enable the comparison 168 of serological data from different platforms (45). Only three papers reported on the SARS-CoV-2 lineage 169 of the re-infection (22, 29, 31) . No studies reported serological measures preceding re-infection with 170

Two studies compared antibody levels between individuals who were re-infected and those who were 172 not. Krutikov et al. did not find a statistically significant difference in anti-N IgG titres (reported as the 173 log10 IgG (AU/ml)) between those who were re-infected compared to those who were not (p=0.544) but 174 did show that individuals who were antibody-negative at the start of the study were at greater risk of 175 infection during the study period than those who were antibody-positive (26). Lumley and colleagues 176 used Poisson regression to compare the incidence rate of infection between seropositive and 177 seronegative individuals (2) , and found that individuals who were anti-S positive were less likely to be 178 infected compared to those who were anti-S negative (incidence rate ratio (IRR) of 0.11 (95% CI 0.03, 179 0.44)). Similar findings were observed using anti-N antibody (IRR = 0.11 (95% CI 0.03, 0.45)). Analysis of 180 the association between continuous antibody concentrations and incidence was also statistically 181 significant for both antibodies (p<0.001) (2) . 182 183 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

We included 11 studies describing breakthrough SARS-CoV-2 infection. These included two case reports 185 (41, 42), one cohort study (40), two case-control studies (34, 43) , and two studies that re-analyzed 186 antibody data from a clinical trial (37, 44) . Five in silico studies utilized statistical methods to explore the 187 association between antibody levels and VE (35-39). The populations studied were either clinical trials or 188 other vaccine study participants (35) (36) (37) (38) (39) 44) or healthcare workers (34, (40) (41) (42) (43) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Four of the six studies compared aggregate antibody levels between cases and non-cases. Gilbert et al. 207 calculated geometric mean concentration (GMC) ratios of cases to non-cases, which ranged from 0.57 208 (95% CI 0.39, 0.84) to 0.71 (95% CI 0.54, 0.94), depending on antibody target and sampling interval (37). 209

Using Cox regression, the authors found statistically significant associations between increasing antibody 210 levels and decreasing risk of COVID-19. Bergwerk et al. applied generalizing estimating equations to 211 predict antibody levels and generate GMT ratios of cases to non-cases. For neutralizing antibodies, these 212 ranged from a case-to-control ratio of 0.15 (95% CI, 0.04, 0.55) at peak values (within the first month 213 after the second vaccine dose) to case-to-control ratio of 0.36 (95% CI 0.17, 0.79) by the week before 214 breakthrough infection (34). Using linear regression, this study demonstrated a statistically significant 215 correlation between cycle threshold (Ct) value of cases and neutralizing antibody level, suggesting an 216 inverse relationship between antibody level and viral load. Feng and colleagues did not find a 217 statistically significant difference between median antibody levels of cases and non-cases, regardless of 218 the antibody assay used (44). However, using a generalized additive model, infection risk was found to 219 be inversely correlated to antibody levels. This result was statistically significant for symptomatic but not 220 asymptomatic COVID-19. Yamamoto et al. found no statistically significant difference in post-vaccination 221 neutralization levels between healthcare workers who experienced a breakthrough infection and 222 matched controls during the Delta wave in Japan (43). The authors found that neutralizing titres were 223 lower against Alpha and Delta variants than the wild-type virus, but were comparable between cases 224 and controls. 225

Five of the 10 breakthrough studies described correlations between antibody levels and VE against 227 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. and 171 (95% CI 57, 519) anti-S binding antibody units (BAU/mL), respectively. These were generated 254 using a random effects meta-analytic approach using BNT162b2, mRNA-1273, ChAdOx1 nCoV-19 or 255

Ad26.COV2.S clinical trial data. The analyses also included reverse cumulative distribution functions to 256 estimate vaccine-specific thresholds of protection. Since thresholds calculated from two doses of mRNA 257 vaccine were extremely high and did not overlap with other calculated thresholds, the authors also 258 generated an anti-S threshold that excluded them (60 (95% CI 35, 102) BAU/mL). Khoury and colleagues 259 used a protective neutralization classification model to estimate the antibody concentration resulting in 260 100% protection, which they estimated to be 28.6% (95% CI 19.2-29.2%) of the mean convalescent 261 antibody level (39). The authors also applied a logistic model to calculate the 50% protective 262 neutralization level, which estimates the antibody titre at which 50% of individuals are protected from 263 infection, and is similar to the protective dose 50% that is sometimes used for influenza virus (46). The 264 50% protective neutralization level was found to be 20.2% (95% CI 14.4, 28.4) of the mean convalescent 265 antibody level for symptomatic disease (corresponding to a neutralization titre of between 1:10 to 1:30 266 in most assays), which the authors estimate corresponds to 54 (95% CI 30-96) international units 267 (IU)/ml. For severe disease, the 50% threshold was estimated to be only 3% (95% CI 0.71, 13.0%) of the 268 mean convalescent level. 269

Studies were assessed for quality after full-text screening (Supplementary Table 2 ). Quality assessment 271 was based on NIH NHLBI criteria (19), which centers on adequate description and transparency of 272 methods, inclusion/exclusion criteria, and definitions. The criteria also includes an assessment of 273 whether outcome variables were reported equally across all study participants. We excluded studies 274 that did not adequately measure antibody levels or were missing information as to when antibody levels 275

were obtained relative to infection, or had missing data or unclear methods related to antibody testing 276 (47-51). Of the included studies, we noted that only five reported peak antibody levels at 30-60 days 277 post infection or vaccination, the time period which would provide the most insight on peak antibody 278 levels (31, 40, (42) (43) (44) . Only seven studies reported antibody levels immediately prior to (within 30 days) 279 re-infection or breakthrough (2, 26, 27, 31, 33, 40, 42) , and only seven studies reporting SARS-CoV-2 280 lineage (22, 29, 34, (41) (42) (43) (44) . 281

Discussion 283

The studies included in this review provided mixed evidence regarding a SARS-CoV-2 CoP, with a lack of 284 standardization between laboratory methodology, assay targets, and sampling time points complicating 285 comparisons and interpretation. Studies examining the relationship between antibody levels and VE 286 presented high correlation coefficients, despite utilizing diverse data that included several vaccines and 287 a variety of assays, VE endpoints and populations (35, 36, 38, 39) . The robust correlations despite data 288 heterogeneity support the concept of an anti-S antibody or neutralizing antibody CoP. Furthermore, 289 several studies that explored differences in GMTs between cases and non-cases (34, 37) or associations 290 between antibody levels and viral load with infection incidence or risk (2, 34, 37, 44) , found statistically 291 significant differences and associations. Taken together, these findings further support an antibody 292 target as a potential correlate. However, while most studies that present aggregate measures support 293 the existence of a humoral CoP, some individual-level data included in our review provided 294 contradictory findings. Individuals described in case reports who experienced re-infection or 295 breakthrough infection had considerable anti-S or neutralizing antibody levels pre-infection, and in some 296 cases were at the upper limit or exceeded the limit of quantification of commercial assays (40, 41) . 297

Similarly, studies that attempted to estimate the contribution of antibody levels to VE measures (36-38) 298

found that a substantial proportion of VE was not explained by antibody levels, suggesting that while 299 important, anti-S or neutralizing antibodies are only one component of protection. These findings 300 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.21.22269667 doi: medRxiv preprint support observations from SARS-CoV-2 vaccine trial data, where one-dose vaccinated individuals are 301 well-protected despite having very low levels of neutralizing antibodies. Consequently, these findings 302 suggest that cellular immunity or non-neutralizing antibodies may also play a role in protection (36, 52) . 303

From the reviewed literature, our analyses indicate that a humoral SARS-CoV-2 CoP may exist, but may 304 be relative, such that the risk of infection is greatly reduced but not eliminated (8, 53). One analogous 305 example of this is the influenza 50% protective dose, defined as the antibody concentration at which the 306 risk of infection is reduced by half (9, 46). This is in contrast to a CoP that provides complete immunity 307 (absolute correlate), as has been shown for viruses like rubella (9, 53). Khoury and colleagues provided 308 evidence for a relative correlate in calculating a "50% protective neutralization level" across vaccine 309 studies, and finding that lower antibody levels are required to prevent severe disease than to prevent 310 infection (39). Estimating different thresholds by outcome is concordant with the concept of a relative 311 threshold (9). Our findings are also in line with real-world observations where SARS-CoV-2 breakthrough 312 cases are often mild or asymptomatic, suggesting that while there is not adequate immunity to prevent 313 infection, there is adequate immunity to prevent symptomatic or severe disease (54-57) . Furthermore, 314 since mRNA vaccines produce high antibody levels while viral vector vaccines result in robust cellular 315 immunity, it is also possible that the CoP following vaccination may differ by vaccine product (38, 52) . 316

The paucity of estimated quantitative thresholds therefore results in mostly indirect evidence included 317 in our review. 318

Other data sources that were not eligible for inclusion in our review are supportive of a humoral CoP. 319

For example, transfer of SARS-CoV-2 convalescent IgG to naïve rhesus macaques was found to be 320 protective in a dose-dependent manner (5). Convalescent plasma has sometimes been found to be 321 therapeutically effective in patients infected with SARS-CoV-2 (58), and monoclonal antibody therapy 322 has been approved in the US for both treatment and prophylaxis (59). Although neither animal models 323 nor manufactured monoclonal antibodies mimic the human immune response precisely, and the 324 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.21.22269667 doi: medRxiv preprint effectiveness of convalescent plasma therapy has been mixed (60), these data underscore the 325 importance of humoral immunity for protection against SARS-CoV-2. 326

There were several limitations to the available literature for this systematic review. Many studies did not 327 meet our inclusion criteria and pre-set definitions, which were designed to minimize bias. Our review 328 included many different study types, including several case-reports, which generally provide a lower 329 level of evidence and are particularly prone to bias (61, 62). There was heterogeneity in the targets that 330

were measured, including neutralizing antibodies or antibody isotypes directed against spike (whole 331 Spike, S1, receptor binding domain) or nucleocapsid protein. The included studies used different 332 laboratory assays, which were generally not comparable. The WHO IS was seldom used, likely because it 333 was not made available until late 2020. The diversity of laboratory assays and results precluded a meta-334 analysis of our data. To overcome the lack of calibration between laboratory assays, some studies 335 normalized results against convalescent sera. However, since the humoral immune response to natural 336 infection varies by age and disease severity (63), this method is not ideal for calibrating results. Most 337 studies did not report which SARS-CoV-2 lineage was associated with the breakthrough or re-infection, 338

with only a few studies reporting antibody levels preceding infection with a VOC. With the emergence of 339 Omicron (B.1.1.529), the lack of Omicron-specific serological data prior to re-infection or breakthrough 340 is unfortunate. Evidence based on in vitro neutralization assays suggests that, for immune responses to 341

Omicron in individuals who have already been exposed to Ancestral SARS-CoV-2 antigens (whether 342 through infection or vaccination), an Omicron CoP may be higher than for Ancestral SARS-CoV-2 or other 343

VOCs, due to the reduced effectiveness of Ancestral antibodies for variant spike protein. To that point, 344

Pfizer-BioNTech has reported a 25-fold reduction in neutralization titres against Omicron compared to 345

Ancestral SARS-CoV-2 in in individuals vaccinated with two doses of BNT162b2 (64). Studies from South 346

Africa and Germany report a reduction in neutralization up to 41-fold (65, 66), despite two or three 347 doses of BNT162b2 or mRNA-1273 and previous infection. However, neutralization levels cannot be 348 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.21.22269667 doi: medRxiv preprint interpreted with regards to immunity in the absence of a CoP. This issue will be further complicated as 349 the proportion of individuals with an Omicron-specific immune response due to infection, re-infection or 350 breakthrough increases, especially if the clinical serology tools available for diagnostic purposes 351 continue to use Ancestral SARS-CoV-2 antigens. 352

Since we restricted our review to evidence on a humoral CoP, we did not examine the role of cellular 353

immunity. This is a limitation because both animal models and human studies have suggested that 354 cellular immunity is likely integral to protection (5). Furthermore, the studies included in our review 355

focused on systemic immunity. Since mucosal antibodies are a known element of SARS-CoV-2 immunity 356 this was another limitation in our analysis (60) Our findings emphasize that further research into the role of humoral immunity, including non-363 neutralizing antibody, Fc effector functions and cellular and mucosal immunity is a priority, especially in 364 the context of immune-evading variants like Omicron. The effect of lineage, vaccine product and the 365 endpoint being measured (i.e. infection, symptomatic disease, severe disease) on the CoP are also 366 essential questions. However, study designs that are best suited to assess whether a CoP exists are also 367 quite complex and intensive. For example, human challenge studies are likely the most direct way to 368 determine a CoP (69), but ethical issues that accompany these types of studies have limited their 369 application (70). Finally, elucidating a CoP is directly related to raising global vaccine coverage and 370 ending the COVID-19 pandemic. Currently, 40.5% of the world's population has not been vaccinated 371 against SARS-CoV-2 (71). The need to approve more vaccines is urgent, but placebo controlled trials 372 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Taken together, our findings suggest that humoral immunity is an integral part of protection against 376 SARS-CoV-2, and that an antibody target is the most likely immune marker for a SARS-CoV-2 CoP. 377

Although the evidence thus far supports the use of SARS-CoV-2 serology test results to confirm prior 378 exposure to SARS-CoV-2, we currently do not have the tools to interpret serology with regards to 379 protection. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. variant of concern Omicron. Cell Mol Immunol. 2022. 445 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. University Hospital -Vienna, January-July 2021; an Exploratory Study on 8 500 Employees with 528 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. COVID-19 case reports, January to April 2020: a meta-epidemiologic study. CMAJ Open. 567 2021;9(1):E295-E301. 568 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Table 1 : Definitions applied to determine cases of re-infection and breakthrough in this systematic review.

Definition SARS-CoV-2 re-infection, suspected case A symptomatic person with a positive molecular test result for SARS-CoV-2 following a period of ≥45 days from the first infection with SARS-CoV-2, or An asymptomatic person with a positive molecular test result for SARS-CoV-2 following a period ≥90 days from the first infection with SARS-CoV-2, for which SARS-CoV-2 shedding from a previous infection, or an infection of a different etiology have been ruled out (74). SARS-CoV-2 re-infection, confirmed case A person who meets the suspected case criteria, but also has a documented time interval for which they were not symptomatic, did not shed SARS-CoV-2 virus or RNA, or had a negative SARS-CoV-2 laboratory test. In addition, the case has had whole genomic sequencing of both the initial and subsequent SARS-CoV-2 virus, with evidence that they belong to different clades or lineages or exhibiting a number of single nucleotide variations that correlate with the probability that each virus is from a different lineage (74).

A positive molecular test result in an individual who received one dose of a vaccine product that is approved in at least one jurisdiction (i.e. -not an experimental vaccine) at least 14 days previously (75).

A positive case molecular test result in an individual who received a second dose of a vaccine product that is approved in at least one jurisdiction (i.e. -not an experimental vaccine) at least seven days previously (1) Table 2 : Summary of articles included in this review following re-infection and breakthrough infection definition screening, and types of evidence they describe.

Included # -Assay results from each study were included for every antibody type (i.e. -anti-S, anti-N, anti-RBD) and isotype (i.e. -IgG, IgM, IgA) measured. In instances where more than one assay target was used to measure the same antibody target in the same study (i.e. both PRNT and pseudoneutralization results, or anti-S results from two different assays), we included only one of these results. Full data extraction for every study can be accessed in Supplementary File 3.

*-If more than one test result was provided, the result closest in time to re-infection is presented. ** -In these studies, other breakthrough infections were reported as well, but with no accompanying temporal and laboratory data Definitions: anti-S = anti-spike, anti-N = anti-nucleocapsid, anti-RBD = anti-receptor binding domain, PRNT = plaque reduction neutralization test, LDT= laboratory-determined test, ELISA = enzyme-linked immunosorbent assay, AU = arbitrary units, OD = optical density, IRR = increased relative risk, HCW = health care worker, LTC = long term care, GMC = geometric mean concentration, GMT = geometric mean titre, 95% CI = 95% confidence interval, ID50 = infectious dose titer 50, WHO IS = World Health Organization SARS-CoV-2 antibody International Standard, HR = hazard ratio, RCT = randomized controlled trial, MSD = Mesoscale Discovery 

Control predicted GMC: 6274 (95% CI

Spike total antibody

Control predicted GMC: 1208 (95% CI

SARS-CoV-2 ancestral, Alpha and Delta strains) Ancestral

Control predicted GMT: 408 (320,520) Alpha: Case predicted GMT: 116 (95% CI 80

155) Delta: Case predicted GMT: 123 (95% CI 85, 177)

In instances where more than one assay target was used to measure the same antibody target in the same study (i.e. -both PRNT and pseudoneutralization results, or anti-S results from two different assays), we included only one of these results. Full data extraction for every study can be accessed in Supplementary File 3.Definitions: anti-S = anti-spike, anti-N = anti-nucleocapsid, anti-RBD = anti-receptor binding domain, PRNT = plaque reduction neutralization test, LDT= laboratory-determined test, ELISA = enzyme-linked immunosorbent assay, OD = optical density, IRR = incidence rate ratio, HCW = health care worker, LTC = long term care, HCS = human convalescent sera, NAAT = nucleic acid amplification testing Records removed before screening: Duplicate records removed (n = 5,974)Title & Abstracts Screened Records excluded (n = 4,800)Reports not retrieved (n = 0)Reports excluded (n=99): Criteria for re-infection not met (n = 9) Immunocompromised population (n = 4) No breakthrough/re-infection (n = 16) Missing or incomplete data (n =39) Non-English/French language (n=2) No primary data (n = 29)Reports excluded (n = 45): Criteria for reinfection not met (n = 3) Immunocompromised population (n= 4) No breakthrough/re-infection (n=4) Missing or incomplete data (n=31) No primary data (n =2)